Success Metrics

Clinical Success Rate
57.1%

Based on 8 completed trials

Completion Rate
57%(8/14)
Active Trials
3(18%)
Results Posted
125%(10 trials)
Terminated
6(35%)

Phase Distribution

Ph phase_1
11
65%
Ph phase_2
2
12%
Ph phase_3
3
18%

Phase Distribution

11

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
11(68.8%)
Phase 2Efficacy & side effects
2(12.5%)
Phase 3Large-scale testing
3(18.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

57.1%

8 of 14 finished

Non-Completion Rate

42.9%

6 ended early

Currently Active

3

trials recruiting

Total Trials

17

all time

Status Distribution
Active(3)
Completed(8)
Terminated(6)

Detailed Status

Completed8
Terminated6
Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
17
Active
3
Success Rate
57.1%
Most Advanced
Phase 3

Trials by Phase

Phase 111 (68.8%)
Phase 22 (12.5%)
Phase 33 (18.8%)

Trials by Status

terminated635%
completed847%
active_not_recruiting318%

Recent Activity

3 active trials
Showing 5 of 17
active_not_recruitingphase_3

A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT03319667
completedphase_3

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

NCT03275285
active_not_recruitingphase_3

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

NCT04270409
terminatedphase_1

A Study of Isatuximab-based Therapy in Participants With Lymphoma

NCT03769181
terminatedphase_1

Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

NCT04294459
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT03319667Phase 3

A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Active Not Recruiting
NCT03275285Phase 3

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

Completed
NCT04270409Phase 3

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Active Not Recruiting
NCT03769181Phase 1

A Study of Isatuximab-based Therapy in Participants With Lymphoma

Terminated
NCT04294459Phase 1

Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

Terminated
NCT04458831

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Active Not Recruiting
NCT04661033Phase 2

Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

Terminated
NCT01084252Phase 1

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Completed
NCT03194867Phase 1

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Completed
NCT02812706Phase 1

Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients

Completed
NCT02513186Phase 1

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

Completed
NCT03733717Phase 1

Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma

Completed
NCT01749969Phase 1

SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

Completed
NCT03637764Phase 1

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Terminated
NCT03367819Phase 1

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Terminated
NCT02999633Phase 2

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Terminated
NCT02283775Phase 1

SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17